These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 11579015

  • 1. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
    Hong X, Wang X.
    Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
    [No Abstract] [Full Text] [Related]

  • 2. Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.
    Teter CJ, Early JJ, Frachtling RJ.
    J Clin Psychiatry; 2000 Nov; 61(11):872-3. PubMed ID: 11105743
    [No Abstract] [Full Text] [Related]

  • 3. Reversible neutropenia with olanzapine following clozapine-induced neutropenia.
    Thangadurai P, Jyothi KS, Gopalakrishnan R, Kuruvilla A, Jacob KS.
    Am J Psychiatry; 2006 Jul; 163(7):1298. PubMed ID: 16816247
    [No Abstract] [Full Text] [Related]

  • 4. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.
    Finkel B, Lerner A, Oyffe I, Rudinski D, Sigal M, Weizman A.
    Int Clin Psychopharmacol; 1998 May; 13(3):133-5. PubMed ID: 9690981
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.
    Dernovsek MZ, Tavcar R.
    Int Clin Psychopharmacol; 2000 Jul; 15(4):237-8. PubMed ID: 10954065
    [Abstract] [Full Text] [Related]

  • 6. Olanzapine: safe during clozapine-induced agranulocytosis.
    Oyewumi LK, Al-Semaan Y.
    J Clin Psychopharmacol; 2000 Apr; 20(2):279-81. PubMed ID: 10770478
    [No Abstract] [Full Text] [Related]

  • 7. Experiences with clozapine and olanzapine.
    Chatterton R.
    Aust N Z J Psychiatry; 1998 Jun; 32(3):463. PubMed ID: 9672741
    [No Abstract] [Full Text] [Related]

  • 8. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
    Swartz JR, Ananth J, Smith MW, Burgoyne KS, Gadasally R, Arai Y.
    J Clin Psychiatry; 1999 Feb; 60(2):119-21. PubMed ID: 10084639
    [Abstract] [Full Text] [Related]

  • 9. Weight gain and antipsychotic medications.
    Aquila R, Emanuel M.
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract] [Full Text] [Related]

  • 10. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.
    Schuld A, Kraus T, Hinze-Selch D, Haack M, Pollmächer T.
    Acta Psychiatr Scand; 2000 Aug; 102(2):153-5. PubMed ID: 10937789
    [Abstract] [Full Text] [Related]

  • 11. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R, Brar JS.
    Psychopharmacol Bull; 1998 Aug; 34(1):83-7. PubMed ID: 9564203
    [Abstract] [Full Text] [Related]

  • 12. Atypical neuroleptics in child and adolescent psychiatry.
    Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E.
    Eur Child Adolesc Psychiatry; 2000 Aug; 9 Suppl 1():I9-19. PubMed ID: 11140784
    [Abstract] [Full Text] [Related]

  • 13. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR.
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract] [Full Text] [Related]

  • 14. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R.
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [Abstract] [Full Text] [Related]

  • 15. Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
    Canuso CM, Hanau M, Jhamb KK, Green AI.
    Am J Psychiatry; 1998 Oct; 155(10):1458. PubMed ID: 9766782
    [No Abstract] [Full Text] [Related]

  • 16. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M, Kuloglu M, Tezcan E, Ustundag B.
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [Abstract] [Full Text] [Related]

  • 17. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [Abstract] [Full Text] [Related]

  • 18. Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
    Webster D, Devarajan S, Gallant J, Harris A, Kopala LC.
    Schizophr Res; 2002 Jul 01; 56(1-2):187-9. PubMed ID: 12084432
    [No Abstract] [Full Text] [Related]

  • 19. Two new atypical antipsychotics: advantages and disadvantages.
    Lemon MD.
    S D J Med; 1998 Aug 01; 51(8):285-6. PubMed ID: 9724957
    [No Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of antipsychotic drugs.
    Meibach RC.
    Am J Psychiatry; 2003 Mar 01; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.